Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Unraveling the Immunological Nexus: Role of Complement Inhibitor Cub and Sushi Multiple Domains 1 (CSMD1) in Schizophrenia Synaptic Pathogenesis
FY 2023-24
Summary
Individuals with schizophrenia (SCZ), a chronic psychiatric disorder affecting 1% of the population, experience hallucinations and delusions that challenge their everyday lives. Although the pathophysiology of SCZ is poorly understood, genome-wide association studies (GWAS) have identified genes linked to the complement system as potential SCZ risk genes. The complement system is known both to enhance innate immunity and regulate synaptic pruning and plasticity. To prevent the aberrant degradation of neuronal synapses by complement proteins, complement is tightly regulated. One such regulator, the Cub and Sushi Domains 1 (CSMD1) has been identified as a potential risk gene for SCZ. Although CSMD1 knock-out mice exhibit a reduction in neuronal spine density, little is currently known of the mechanisms by which CSMD1 may influence SCZ risk and pathogenesis in humans. The overall goal of the proposed study is to gain a deeper understanding of the role of CSMD1 in SCZ. Specifically, we aim to investigate whether CSMD1 gene and protein expression levels are altered in postmortem brain tissue in SCZ, compared to controls, and whether CSMD1 expression correlates with levels of markers of synaptic density in the human brain. Furthermore, we will investigate whether CSMD1 levels are lower in blood in SCZ, both early, at the first episode of psychosis (FE). Results could lead to the identification of early biomarkers in FE psychosis patients as well as possible biomarkers of response to existing treatments, allowing for early detection and intervention while paving the way toward the development of complement-based therapies for SCZ.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
525508
Name
freidel Ninon
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Unraveling the Immunological Nexus: Role of Complement Inhibitor Cub and Sushi Multiple Domains 1 (CSMD1) in Schizophrenia Synaptic Pathogenesis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Complement System; Cub And Sushi Multiple Domains (Csmd1); Immune System; Neurodevelopment; Neuropsychiatric Disorder; Pathogenesis; Schizophrenia; Schizophrenia Risk Genes (Gwas); Synaptic Plasticity; Synaptic Prunning
Abstract
Individuals with schizophrenia (SCZ), a chronic psychiatric disorder affecting 1% of the population, experience hallucinations and delusions that challenge their everyday lives. Although the pathophysiology of SCZ is poorly understood, genome-wide association studies (GWAS) have identified genes linked to the complement system as potential SCZ risk genes. The complement system is known both to enhance innate immunity and regulate synaptic pruning and plasticity. To prevent the aberrant degradation of neuronal synapses by complement proteins, complement is tightly regulated. One such regulator, the Cub and Sushi Domains 1 (CSMD1) has been identified as a potential risk gene for SCZ. Although CSMD1 knock-out mice exhibit a reduction in neuronal spine density, little is currently known of the mechanisms by which CSMD1 may influence SCZ risk and pathogenesis in humans. The overall goal of the proposed study is to gain a deeper understanding of the role of CSMD1 in SCZ. Specifically, we aim to investigate whether CSMD1 gene and protein expression levels are altered in postmortem brain tissue in SCZ, compared to controls, and whether CSMD1 expression correlates with levels of markers of synaptic density in the human brain. Furthermore, we will investigate whether CSMD1 levels are lower in blood in SCZ, both early, at the first episode of psychosis (FE). Results could lead to the identification of early biomarkers in FE psychosis patients as well as possible biomarkers of response to existing treatments, allowing for early detection and intervention while paving the way toward the development of complement-based therapies for SCZ.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
freidel, Ninon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~